Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The vaccine hesitancy comes despite serious risks from COVID-19 for people diagnosed with blood cancers such as leukemia and lymphoma.
Nearly a quarter of patients treated with the peptide-drug conjugate experienced partial remission.
After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.
Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.
The coronavirus vaccines are safe and should be effective even for people with advanced cancer.
Damon Runyon Cancer Research Foundation shares some exciting discoveries made by Damon Runyon researchers in 2020.
Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.
Studies ask whether cancer treatment, such as chemotherapy and immunotherapy, can lead to more severe COVID-19.
Poorer outcomes for Black and Hispanic patients significantly depend on where they live.
Despite being the only current cure for MDS, transplants generally haven’t been offered to older patients.
The drug targets cancer’s survival proteins, making them more vulnerable to treatments that cause cancer cells to self-destruct.
Those with blood cancers are nine times more likely to be hospitalized or die from the flu.
Some patients develop a secondary blood cancer after receiving radiation or chemotherapy treatment for their initial cancer diagnosis
Some might say that rejoicing over my numbers at this stage is slightly premature.
As my coughing has gotten more noticeable the last few nights, I have again become quite concerned. Could I have lung cancer too?
The trial will test the drug acalabrutinib in those with acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.